IceCure Medical Ltd. (ICCM)

NASDAQ: ICCM · IEX Real-Time Price · USD
2.74
0.02 (0.74%)
At close: Jan 14, 2022 4:00 PM
2.66
-0.08 (-2.92%)
After-hours:Jan 14, 2022 4:49 PM EST
Market Cap87.19M
Revenue (ttm)3.91M
Net Income (ttm)-5.27M
Shares Out31.82M
EPS (ttm)-0.32
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume25,491
Open2.74
Previous Close2.72
Day's Range2.61 - 2.74
52-Week Range2.60 - 12.40
Beta1.73
AnalystsStrong Buy
Price Targetn/a
Earnings Daten/a

About ICCM

IceCure Medical is a commercial stage medical device company focusing on the research, development and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. In the United States our products are approved as a “single family” known as the “IceCure Family,” which includes the IceSense3, ProSense, and MultiSense (which has not been commercialized) cryoablation systems. Cryoablation is the process by which benign and malignant tumors are ablated (destroyed) through freezing such tumors whi...

IndustryMedical Care Facilities
IPO DateAug 26, 2021
CEOEyal Shamir
Employees40
Stock ExchangeNASDAQ
Ticker SymbolICCM
Full Company Profile

Financial Performance

Financial Statements

News

IceCure Medical CEO Issues Letter to Shareholders

CAESAREA, Israel, Jan. 5, 2022 /PRNewswire/ --  IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense® Syst...

1 week ago - PRNewsWire

IceCure Medical Receives Notice of Intention to Grant a European Patent Covering Its Cryogenic Pump

CAESAREA, Israel, Dec. 20, 2021 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense® Syst...

3 weeks ago - PRNewsWire

IceCure Medical Ltd. Closes $17 Million Underwritten Public Offering and Partial Exercise of Over-Allotment Option

CAESAREA, Israel, Dec. 13, 2021 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) (the "Company" or "IceCure"), developer of minimally-invasive cryoablation technology, the ProSense® Syst...

1 month ago - PRNewsWire

IceCure Medical Ltd. Announces Pricing of $15 Million Underwritten Public Offering

CAESAREA, Israel, Dec. 9, 2021 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) (the "Company" or "IceCure"), developer of minimally-invasive cryoablation technology, the ProSense® Syste...

1 month ago - PRNewsWire

IceCure Medical's Interim Results of the ICE3 Clinical Trial for Early-Stage Breast Cancer Cryoablation featured at t...

CAESAREA, Israel, Dec. 2, 2021 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense® Syste...

1 month ago - PRNewsWire

IceCure Medical Announces Appointment of Merav Nir Dotan to Vice President Human Resources

CAESAREA, Israel, Nov. 29, 2021 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense® Syst...

1 month ago - PRNewsWire

IceCure Medical Reports Financial Results as of and for the first Nine Months of 2021 and Recent Corporate Developments

CAESAREA, Israel, Nov. 23, 2021 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of next-generation, minimally-invasive cryoablation technology wi...

1 month ago - PRNewsWire

IceCure Medical Announces New Independent Data Published in the Journal of Cancer Therapy Showing that Percutaneous C...

CAESAREA, Israel, Nov. 1, 2021 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of the next generation minimally invasive cryoablation technology ...

2 months ago - PRNewsWire

IceCure Medical Enters into an Exclusive Agreement in Poland for Distribution of the ProSense™ Cryoablation System

CAESAREA, Israel, Oct. 20, 2021 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of the next generation minimally invasive cryoablation technology...

2 months ago - PRNewsWire

IceCure Medical Announces Updated Regulatory Strategy in China for the IceSense3® System to Treat Cancerous Tumors wi...

CAESAREA, Israel, Oct. 12, 2021 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of the next generation minimally invasive cryoablation technology...

3 months ago - PRNewsWire